181464-29-9

Upstream product

• 181421-53-4 (3S,4R)-4-{(1R,2S,3S)-3-[2-(tert-Butyl-dimethyl-silanyloxy)-ethoxy]-2-hydroxy-cyclohexyl}-3-[(R)-1-(tert-butyl-dimethyl-silanyloxy)-ethyl]-azetidin-2-one 
• 181421-47-6 (3S,4R)-3-[(R)-1-(tert-Butyl-dimethyl-silanyloxy)-ethyl]-4-[(1R,2S,3S)-2-hydroxy-3-(2-hydroxy-ethoxy)-cyclohexyl]-azetidin-2-one 
• 135297-04-0 (3S,4R)-4-[(1R,2S,3R)-2,3-epoxycyclohexyl]-3-[(R)-1-(tert-butyldimethylsilyloxy)ethyl]azetidin-2-one 
• 74503-07-4 allyl oxalyl chloride 
• 144572-86-1 (3S,4R)-4-{(1R,3S)-3-[2-(tert-Butyl-dimethyl-silanyloxy)-ethoxy]-2-oxo-cyclohexyl}-3-[(R)-1-(tert-butyl-dimethyl-silanyloxy)-ethyl]-azetidin-2-one 

Relevant academic research and scientific papers

Synthesis and biological evaluation of 4-alkoxy substituted trinems. Part 1

Synthesis of new 4-alkoxy substituted trinems 4, 5, 6, 7 and 8 together with their antibacterial profiles compared to imipenem and GV104326 (2) are described. The good antibacterial profile observed for derivatives 4-7 encouraged further exploration of these derivatives.

Synthesis and biological evaluation of 4-alkoxysubstituted trinems. Part II

The synthesis and the microbiological evaluation of a novel series of substituted tricyclic β-lactam derivatives (trinems, former named tribactams) is reported. Suitable basic groups were introduced within the key C-4 side chain with the aim of improving the antibacterial activity of this class of new antibiotics to Pseudomonas spp.. Among the different compounds prepared, basic derivatives 2 and 3 showed improved activity with respect to GV104326 1 against these highly resistant strains.